stat3-blocked whole-cell hepatoma vaccine

A **tumor cell lysate vaccine** composed of **whole-cell lysates from hepatocellular carcinoma (HCC) cells** (specifically, H22 and Hepa1–6 murine cell lines) in which the **STAT3 signaling pathway is blocked** by transfection with a **STAT3 decoy oligodeoxynucleotide**. The inactivated tumor cells are used to prepare the vaccine, which is designed to induce robust anti-tumor immune responses. Mechanistically, blockage of STAT3 in HCC cells enhances their immunogenicity, leading to stimulation of T cells, natural killer (NK) cells, dendritic cell maturation, a decrease in regulatory T cells (Tregs), reduced production of immunosuppressive cytokines (TGF-β and IL-10), increased tumor-specific IgG antibody production, and attenuation of immune checkpoint molecule expression (e.g., PD-1, TIGIT) on T cells and NK cells. The vaccine has been shown in mouse models to inhibit HCC tumor growth, prolong survival, generate immunological memory, and prime secondary immune responses against HCC. The approach aims to reset the tumor immune microenvironment and may be applicable to other cancer types characterized by STAT3 overactivation[1][3][5].

Other names

stat3-blocked whole-cell HCC vaccinestat-3-blocked whole-cell HCC vaccinestat 3-blocked whole-cell HCC vaccinestat3-decoy ODN HCC whole-cell lysate vaccinestat-3-decoy ODN HCC whole-cell lysate vaccinestat 3-decoy ODN HCC whole-cell lysate vaccine